Pharmacy Times

JULY 22, 2022

Pharmacists discuss the impacts of inaccuracy on vaccine hesitancy and offer communication strategies for conversations with patients.

Vaccines 123

Vaccines Communication 123

Drug Topics

NOVEMBER 11, 2022

Communication and education are critical to patient confidence in emergency use authorization vaccines.

Vaccines 98

Vaccines Communication 98

pharmaphorum

MAY 19, 2022

The likelihood of long COVID symptoms was found to decrease after COVID-19 vaccination, and evidence pointed to an even greater improvement after a second dose. However, the authors say more data is needed before vaccination can be considered a treatment for the condition.

Vaccines 123

Vaccines Immunization Communication 123

Pharmacy Times

APRIL 27, 2023

The analysis, published in Nature Communications, demonstrates glycan trimming also keeps the antibody response away from immunodominant glucan holes and patches.

Communication 132

Communication Vaccines 132

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccines 98

Vaccines Immunization Communication 98

pharmaphorum

NOVEMBER 19, 2020

Amid the turmoil and the race to not only find a vaccine but also help to care for those who are battling the long-term effects of COVID-19, healthcare organisations need to sharpen their communication skills. Good, empathetic design allows the science to shine.

Communication 79

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 79

Pharmaceutical Technology

FEBRUARY 23, 2023

GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. The post GenScript ProBio and RVAC partner for Covid-19 vaccine pDNA appeared first on Pharmaceutical Technology.

Vaccines 115

Vaccines Communication 115

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.

Vaccines 93

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 93

Digital Pharmacist

AUGUST 21, 2023

The most effective preventive measure against the flu is getting an annual flu vaccine. Getting Vaccinated for the Flu The CDC says ideally, everyone who is eligible for a flu vaccine should be vaccinated by the end of October – the ideal time to get vaccinated being September or October.

Vaccines 98

Vaccines Communication Immunization 98

Pharmafile

JANUARY 23, 2023

Indian biotech company Bharat Biotech plans to launch its new intranasal COVID-19 vaccine iNCOVACC on the 26 January 2023 ‒ the vaccine is the first of its kind to be developed in India. read more

Vaccines 98

Vaccines Communication 98

Pharmafile

MARCH 2, 2023

Yesterday, GSK shared that an advisory committee from the FDA voted in support of its respiratory syncytial virus (RSV) vaccine candidate for older adults. This support is ahead of an official FDA approval for the company’s vaccine. GSK has shared that a final decision is expected to be made by the FDA ahead of the 3 May. read more

Vaccines 98

Vaccines FDA Communication 98

pharmaphorum

JANUARY 20, 2021

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. That suggests that patients could get SARS-CoV-2 twice, but also that the current crop of vaccines may not be as effective.

Vaccines 98

Vaccines Communication Immunization 98

pharmaphorum

DECEMBER 17, 2020

Tik Tok is unlikely to spring to mind as a source of reliable information about complex issues, but scientists are using it to fly the flag for COVID-19 vaccines and other health topics. When we talk about vaccines as health professionals, people who are vehemently anti-vaccine can take it out of context for their agenda.

Vaccines 94

Vaccines Communication Immunization 94

Omnicell

JANUARY 10, 2023

Director Regional Operations, EnlivenHealth The biggest vaccination campaign in history is underway and scaling fast. COVID-19 vaccines are now being distributed across the USA and administered to an expanding universe of patient populations. And that’s where technology becomes imperative. are preparing for the next phase.

Vaccines 52

Vaccines Omnicell Communication 52

Pharmafile

SEPTEMBER 9, 2022

A new malaria vaccine could be pivotal in the fight against the deadly disease. This vaccine has been developed by members of the University of Oxford team behind the AstraZeneca COVID-19 jab. read more.

Vaccines 81

Vaccines Communication 81

Pharmaceutical Technology

JUNE 8, 2023

Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). The Phase I CORAL-BOOST dose-escalation trial (NCT05148962) evaluated Gritstone’s samRNA candidate (GRT-R910) in previously vaccinated healthy older adults.

Vaccines 52

Vaccines Immunization Communication 52

Pharmaceutical Technology

MARCH 23, 2023

China’s National Medical Products Administration (NMPA) has granted emergency use authorisation (EUA) for CSPC Pharmaceutical Group’s messenger RNA (mRNA) vaccine, SYS6006, to treat Covid-19. With this regulatory approval, CSPC Pharmaceutical is claimed to be the first company to receive approval for providing an mRNA vaccine in the country.

Vaccines 52

Vaccines Communication 52

Pharmaceutical Technology

NOVEMBER 30, 2022

in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments.

Vaccines 59

Vaccines Communication 59

Pharmafile

APRIL 24, 2023

Sanofi has introduced a hepatitis A vaccine for children aged between one to 15 years old in the UK. The vaccine, inactive AVAXIM Junior, will consist of two doses injected intramuscularly six to 36 months apart. It is the most common form of viral hepatitis and the third most common vaccine-preventable infection among travellers.

Vaccines 59

Vaccines Communication 59

STAT

FEBRUARY 12, 2024

We accept all manner of confidential communications and secret dossiers … New diabetes and weight loss drugs may benefit patients undergoing hip replacement without adding to complication risks , Reuters reports, citing preliminary data released at a meeting of orthopedic surgeons. Meanwhile, here are a few tidbits to digest.

Vaccines 90

Vaccines Communication Hospitals 90

Pharmacy Times

AUGUST 2, 2023

Experts discuss strategies that can be employed to communicate the significance of yearly flu vaccines to patients and improve patient- centered care offered by pharmacists.

Communication 65

Communication Vaccines 65

Pharmafile

JANUARY 13, 2023

The FDA, along with Taiwanese medical institutions, have been evaluating Pfizer’s mRNA COVID-19 vaccine, questioning the CDC’s omission of known severe “adverse events of special interest” (AESIs) which appeared in post-vaccination studies. read more. read more.

Vaccines 78

Vaccines FDA Communication 78

pharmaphorum

MARCH 4, 2021

Germany has decided that AstraZeneca’s COVID-19 vaccine should be approved for use in the over-65s after all, reversing its earlier restriction in that age group. . France has said the vaccine can be used in people aged up to 74, rather than the entire over 65s age group. million doses unused.

Vaccines 64

Vaccines Communication 64

Pharmafile

DECEMBER 23, 2022

BioNTech has announced the start of its new first-in-human phase 1 trial for BNT165b1, a candidate from its programme which aims to develop a multi-antigen malaria vaccine.

Vaccines 80

Vaccines Communication 80

Pharmafile

APRIL 19, 2023

The FDA has announced its amendment of the emergency use authorisations (EUAs) for the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines in an attempt to simplify the vaccination programme. These amendments mean that: read more

Vaccines 52

Vaccines FDA Communication 52

Omnicell

SEPTEMBER 5, 2022

Danny Sanchez VP and General Manager, EnlivenHealth® As news emerged about the positive COVID-19 vaccine trial results from Pfizer and its German partner BioNTech, the attention turned to how the vaccine would be distributed and administered to 330 million Americans.

Vaccines 52

Vaccines Documentation Communication 52

Pharmafile

APRIL 28, 2023

Pfizer has announced that the US Food and Drug Administration (FDA) has approved its PREVNAR 20 (20-valent pneumococcal conjugate vaccine) for the prevention of invasive pneumococcal disease (IPD) in infants and children from six weeks to 17 years of age. read more

Vaccines 59

Vaccines FDA Communication 59

pharmaphorum

MARCH 18, 2021

The World Health Organization has backed the safety of the Oxford University/AstraZeneca vaccine ahead of a key announcement from European safety experts later today. Several major European countries including Germany, Italy and France have temporarily suspended use of the vaccine amid fears that it could be linked to blood clots.

Vaccines 52

Vaccines Communication 52

Pharmafile

APRIL 27, 2023

GSK has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has shared a positive opinion on its respiratory syncytial virus (RSV) vaccine candidate for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults over the age of 60. read more

Vaccines 52

Vaccines Communication 52

Pharmaceutical Technology

DECEMBER 21, 2022

This Moderna Innovation and Technology Centre (MITC) is expected to offer access to a locally produced future mRNA vaccine portfolio against respiratory viruses, subject to regulatory evaluation and licensure. Additionally, the centre is anticipated to have to capacity to make up to 250 million doses of vaccines per year.

Vaccines 140

Vaccines Communication 140

Pharmafile

DECEMBER 9, 2022

Pfizer has announced that the FDA has accepted its application for a respiratory syncytial virus (RSV) vaccine for older adults, with the FDA expected to come to a decision by Spring 2023. The FDA will review the application under the priority review programme, meaning the approval timeline should be reduced by four months. read more.

Vaccines 59

Vaccines FDA Communication 59

Pharmafile

FEBRUARY 20, 2023

Valneva and Pfizer have seen their Lyme disease vaccine study cut down after some clinical trial sites were revealed to be not adhering to Good Clinical Practice (GCP) standards. Almost half of the trial’s participants will be withdrawn following these GCP violations. read more

Vaccines 52

Vaccines Communication 52

Pharma Times

NOVEMBER 8, 2023

Communicable diseases account for 50% of all deaths in LMICs - News - PharmaTimes

Communication 55

Communication Vaccines 55

IDStewardship

MAY 12, 2023

For example in infectious diseases we have things like tropical medicine, travel vaccines, microbiology breakpoints, immunocompromised hosts, infection prevention, and regulatory requirements. Establish an open line of communication with your residency program director Different strokes for different folks!

Communication 130

Communication Documentation Vaccines 130

Pharmafile

DECEMBER 15, 2022

The two Ebola vaccines developed by Johnson & Johnson and Merck appeared successful according to two studies: they both produced virus-fighting antibodies after 14 days which appear to remain detectable at various levels for at least a year. The jabs also seem to be safe in both children and adults. read more.

Vaccines 45

Vaccines Communication 45

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial. “But it may be; and if it doesn’t other novel vaccines with similar benefits may well take on this role.”

Vaccines 125

Vaccines Immunization Communication 125

Pharmaceutical Technology

DECEMBER 18, 2022

The 0.25mL dose of the booster vaccine could potentially be used in the European Union (EU) following authorisation in these children a minimum of three months following a previous Covid-19 vaccination. 1273.214, a bivalent Omicron-targeting Covid-19 vaccine of the company. 5), mRNA-1273.

Vaccines 121

Vaccines Communication 121